Saricaoğlu Hayriye, Karadogan Serap Köran, Başkan Emel Bülbül, Tunali Sükran
Department of Dermatology, Medical Faculty, University of Uludağ, Görükle, Bursa, Turkey.
Photodermatol Photoimmunol Photomed. 2003 Oct;19(5):265-7. doi: 10.1034/j.1600-0781.2003.00051.x.
Recently, UVB lamps with a peak emission around 311 nm have been used successfully for the treatment of many dermatologic diseases known to be treated with psoralen plus UVA (PUVA). Narrowband UVB (NBUVB) radiation causes less erythema and carcinogenicity with lower cumulative doses than PUVA, while the treatment response remains high. Lichen planus (LP) is a cell-mediated immune response of unknown origin.
We present our results of NBUVB therapy administered to 10 LP patients. The sessions were administered three to four times weekly with an average cumulative dose of 17.7+/-1.6 J/cm2.
Five patients responded completely, and four were partially responsive at the end of the 30th session. Three of the partially responsive cases responded completely at the 31st, 36th and 51st sessions, respectively.
Clinical improvements observed in our study as well as the potential advantages of NBUVB imply that it is an inevitable treatment alternative for resistant cases of LP.
最近,峰值发射波长约为311nm的中波紫外线(UVB)灯已成功用于治疗许多已知可用补骨脂素加紫外线A(PUVA)治疗的皮肤病。与PUVA相比,窄谱中波紫外线(NBUVB)辐射在累积剂量较低时引起的红斑和致癌性较小,而治疗反应仍然很高。扁平苔藓(LP)是一种病因不明的细胞介导的免疫反应。
我们展示了对10例LP患者进行NBUVB治疗的结果。治疗每周进行三到四次,平均累积剂量为17.7±1.6J/cm²。
5例患者完全缓解,4例在第30次治疗结束时部分缓解。3例部分缓解的病例分别在第31次、36次和51次治疗时完全缓解。
我们研究中观察到的临床改善以及NBUVB的潜在优势表明,它是LP耐药病例不可避免的治疗选择。